World Bank Pharmaceuticals

Pharmaceuticals have a major impact on health, on government and household spending, and on health systems. Despite the fundamental role of pharmaceuticals, there remains a profound gap between the benefit which pharmaceuticals have to offer and th...

Full description

Bibliographic Details
Main Authors:	Govindaraj, Ramesh, Reich, Michael R., Cohen, Jillian C.
Format:	Working Paper
Language:	English en_US
Published:	World Bank, Washington, DC 2013
Subjects:	APPRAISAL REPORTS BIDDING CAPACITY BUILDING CASE STUDY CONTRACEPTIVES CORRUPTION COUNTERFEIT DRUGS DECISION MAKING DELIVERY SYSTEMS DEVELOPED COUNTRIES DEVELOPING COUNTRIES DEVELOPING COUNTRY DEVELOPMENT GOALS DEVELOPMENT INDICATORS DEVELOPMENT NETWORK DEVELOPMENT PARTNERS DEVELOPMENT STUDIES DISTRIBUTION SYSTEMS DRUG FINANCING DRUG INDUSTRY DRUG POLICY DRUG SELECTION ECONOMIC GROWTH ECONOMICS ESSENTIAL DRUGS FINANCIAL SUPPORT FORMAL POLICY HEALTH CARE HEALTH CARE PROVISION HEALTH EXPENDITURES HEALTH NEEDS HEALTH OUTCOMES HEALTH POLICY HEALTH SECTOR HEALTH WORKERS HEPATITIS B HOUSEHOLD INCOME HUMAN CAPITAL HUMAN DEVELOPMENT IMPORTED DRUGS IMPROVED HEALTH INCOME COUNTRIES INDIVIDUAL COUNTRIES INSTITUTIONAL ANALYSIS INTERNATIONAL MARKET INTERVENTION LOW-INCOME COUNTRIES MALARIA MANAGEMENT MANAGEMENT CAPACITY MANAGERS MARKET FAILURES MARKET INCENTIVES MEDICAL SUPPLIES MEDICINE MEDICINES MOTIVATION NATIONAL DRUG POLICIES NATIONAL DRUG POLICY NATIONAL ESSENTIAL DRUG LISTS NATIONAL ESSENTIAL DRUGS LISTS NATIONAL POLICIES NDP NON- GOVERNMENTAL ORGANIZATIONS NUTRITION PARTNER INSTITUTIONS PARTNERSHIP PATENTS PATIENTS PHARMACEUTICAL COMPANIES PHARMACEUTICAL FINANCING PHARMACEUTICAL INDUSTRY PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MARKETING PHARMACEUTICAL MARKETS PHARMACEUTICAL POLICIES PHARMACEUTICAL POLICY PHARMACEUTICAL PRICING PHARMACEUTICAL PROCUREMENT PHARMACEUTICAL PRODUCTION PHARMACEUTICAL PRODUCTS PHARMACEUTICAL REFORM PHARMACEUTICAL REGULATORY AGENCIES PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICAL SYSTEMS PHARMACEUTICAL WAREHOUSING PHARMACEUTICALS PHARMACIES POLICY ANALYSIS POLICY DIALOGUE POLICY DOCUMENT POLICY FRAMEWORK POLICY IMPLICATIONS POLICY PROCESS PRICE COMPARISONS PRIMARY HEALTH CARE PRIVATE SECTOR PRIVATE SECTORS PROJECT IMPLEMENTATION PUBLIC AGENCIES PUBLIC HEALTH PUBLIC POLICIES PUBLIC POLICY PUBLIC SECTOR PURCHASING QUALITY ASSURANCE QUALITY CONTROL RATIONAL USE OF DRUGS SAFETY SCHOOLS SOCIAL MARKETING STRUCTURAL ADJUSTMENT TASK TEAM LEADERS TECHNICAL ASSISTANCE THERAPIES VACCINES WIDESPREAD CORRUPTION WORKERS PHARMACEUTICALS BURDEN OF DISEASE HEALTH CARE SYSTEMS MULTILATERAL ORGANIZATIONS HEALTH CARE FINANCE HEALTH CARE FINANCING HEALTH SYSTEMS DEVELOPMENT & REFORM
Online Access:	http://documents.worldbank.org/curated/en/2000/09/3928594/world-bank-pharmaceuticals http://hdl.handle.net/10986/13734

Description
Summary:	Pharmaceuticals have a major impact on health, on government and household spending, and on health systems. Despite the fundamental role of pharmaceuticals, there remains a profound gap between the benefit which pharmaceuticals have to offer and the reality that for millions of people -- particularly poor and disadvantaged people -- medicines are unavailable, unaffordable, unsafe or improperly used. This World Bank Pharmaceuticals Discussion Paper provides a pragmatic analysis of some of the causes for this gap and strategic directions to help close this gap. The strategic directions outlined in this Pharmaceuticals Discussion Paper complement and reinforce the objectives outlined in the WHO Medicines Strategy: 2000-2003 (World Health Organization, Geneva, 2000, WHO/EDM/2000.1). The WHO strategy describes specific objectives, expected outcomes, and progress indicators in the areas of drug policy, access to essential drugs, quality and safety, and rational use of medicines. Both the World Bank and the WHO initiatives rest on a fundamental commitment to work with governments, on governmental organizations, the private sector, professional bodies, and other key actors to help strengthen the pharmaceutical sector and its ability to contribute to improved health outcomes.. The current burden of disease falling on the two billion people living on less than one dollar per day undermines both individual well-being and collective economic development. Much of this burden of disease can be reduced by securing the availability, affordability, and rational use of essential drugs of assured quality. Yet this aim can not be achieved by governments alone, by individual multilateral organizations working alone, or by any other individual organization. It can only be achieved when committed governments and local organizations are supported by clear, consistency, and mutually compatible approaches by agencies such as the World Bank, WHO, UNICEF, others in the UN family, bilateral donors, and the broader development community. This discussion paper provides an important contribution to this process.

World Bank Pharmaceuticals

Similar Items